Pacer Advisors’s Cabaletta Bio CABA Stock Holding History

Pacer Advisors’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-589	Closed	-$4.41K	–	2583
2024 Q2	$4.41K	Sell	589 -1,064	-64%	-$13K	﹤0.01%	3646
2024 Q1	$28.2K	Buy	+1,653	New	+$35.5K	﹤0.01%	3374

Other funds holding CABA

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Pacer Advisors's CABA Position: Q3 2024 in Review

Pacer Advisors sold out of Cabaletta Bio (CABA) in Q3 2024, closing a stake of 589 shares — an estimated $4.41K sold.

Pacer Advisors first reported a position in CABA in Q1 2024 and held it in 2 quarters. The position peaked at $28.2K in Q1 2024. 120 funds tracked by Wall St. Rank hold CABA as of Q3 2024.

Pacer Advisors reported no remaining Cabaletta Bio position as of Q3 2024 after selling out during the quarter.
Pacer Advisors sold 589 Cabaletta Bio shares in Q3 2024, an estimated $4.41K.
Pacer Advisors first reported a position in Cabaletta Bio in Q1 2024 and held it in 2 quarters.
Pacer Advisors's Cabaletta Bio position peaked at $28.2K in Q1 2024.
120 funds tracked by Wall St. Rank held Cabaletta Bio as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.